Incyte CEO sees $2B Vega deal aiding a post-Jakafi future

Bill Meury, Incyte CEO June 8, 2026 03:01 PM EDT Deals In­cyte's Meury, now a buy­er, sees $2B Ve­ga deal as a step in blood treat­ments be­yond Jakafi Kyle LaHucik Biotech Correspondent Bill Meury has been in or led the C-suite of sev­er­al bio­phar­ma com­pa­nies that have con­struct­ed multi­bil­lion-dol­lar ex­its over the past decade: Al­ler­gan, Karuna and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER